Natera (NASDAQ:NTRA) Insider Sells $243,656.89 in Stock

by · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 1,013 shares of the stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total transaction of $243,656.89. Following the sale, the insider directly owned 143,686 shares in the company, valued at $34,560,793.58. This trade represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

  • On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $285,192.00.
  • On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
  • On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
  • On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
  • On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
  • On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
  • On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.

Natera Price Performance

NASDAQ NTRA traded down $4.45 during trading hours on Thursday, hitting $231.48. The company’s stock had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The company’s 50 day simple moving average is $235.90 and its two-hundred day simple moving average is $193.29. The company has a market cap of $32.02 billion, a P/E ratio of -101.08 and a beta of 1.62.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. During the same period in the previous year, the business earned ($0.26) EPS. The business’s revenue was up 34.7% compared to the same quarter last year. As a group, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Institutional investors have recently bought and sold shares of the business. Horizon Investments LLC bought a new position in shares of Natera during the 3rd quarter valued at approximately $32,000. Hilltop National Bank bought a new stake in shares of Natera in the second quarter valued at about $33,000. Sound Income Strategies LLC lifted its position in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the period. Flagship Harbor Advisors LLC bought a new stake in Natera during the fourth quarter valued at about $41,000. Finally, Quent Capital LLC acquired a new stake in Natera in the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NTRA shares. Stephens raised their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Guggenheim boosted their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Finally, BTIG Research lifted their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Get Our Latest Stock Analysis on Natera

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Articles